News | May 03, 2023
Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey
UAB Medexy's first order under the Distribution Agreement is for over 5000 units of SHIR and RELIEF&GO products
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Super-Bond is made up of a polymerization initiator, a liquid and a polymer powder
The partnership will capitalize on the combined capabilities of the two organizations
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Subscribe To Our Newsletter & Stay Updated
